- Home
- GNSS vs IMA Comparison
GNSS vs IMA Comparison
Compare GNSS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNSS | IMA |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.0M | 66.3M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNSS | IMA |
|---|---|---|
| Price | $1.32 | $4.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $3.87 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 66.4K | 13.6K |
| Earning Date | 08-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,306,790.00 | $800,000.00 |
| Revenue This Year | $39.82 | N/A |
| Revenue Next Year | $12.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.50 | N/A |
| 52 Week Low | $1.31 | $3.90 |
| 52 Week High | $2.47 | $9.10 |
Technical Indicators
Market Signals| Indicator | GNSS | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 28.75 | 21.51 |
| Support Level | N/A | $3.94 |
| Resistance Level | $1.60 | $6.10 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 2.13 | 16.93 |
Price Performance
Historical ComparisonAbout GNSS Genasys Inc.
Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.